SCHEMBL3149871

SCHEMBL3149871

NS(=O)(=O)c1cc2ccccc2c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.59
CA2 P00918 7/20 0.59
CA9 Q16790 6/20 0.59
TRPM4 Q8TD43 1/20 0.54
LDHA P00338 1/20 0.52
CA12 O43570 5/20 0.50
CYP2C9 P11712 2/20 0.50
HSD17B10 Q99714 2/20 0.50
MCL1 Q07820 1/20 0.50
CDK2 P24941 1/20 0.47
MAOA P21397 2/20 0.47
LOXL2 Q9Y4K0 2/20 0.47
LMNA P02545 1/20 0.44
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390404 0.81 MPL (0.53) TRPM4CYP2C9HSD17B10MAOALOXL2
SCHEMBL11772120 0.81 PAX8 (0.45) CA1CA2CA9TRPM4CA12
SCHEMBL4559508 0.80 CA1 (0.60) CA1CA2CA9TRPM4LDHA
SCHEMBL3149642 0.80 CA2 (0.78) CA1CA2CA9LDHACA12
SCHEMBL11575592 0.80 CA1 (0.55) CA1CA2CA9TRPM4LDHA
SCHEMBL1807638 0.80 CA2 (0.60) CA1CA2CA9TRPM4LDHA
SCHEMBL15428777 0.80 CA2 (0.58) CA1CA2CA9LDHACA12
SCHEMBL11775426 0.79 MPL (0.51) TRPM4CYP2C9HSD17B10MAOALOXL2
SCHEMBL10817165 0.79 NQO2 (0.62) CA1CA2CA9TRPM4LDHA
SCHEMBL1807639 0.79 CA2 (0.58) CA1CA2CA9TRPM4LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-01 US disclosed
EP-2133343-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-12-16 EP disclosed
EP-2003135-A9 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-04-22 EP disclosed
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound NISSAN CHEMICAL INDUSTRIES, LTD (JP) 2009-02-12 US disclosed
EP-2003135-A2 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND OSTC, EEF1D, SQLE CA1 1072/4885CA2 783/4885CA9 375/4885
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound CYP2C19, CYP2C9, CYP1A2 CA1 1412/4885CA2 338/4885CA9 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.